No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

SOLIUS White Paper Released: Explores Potential Impact of Vitamin D On COVID-19

Editor: What To Know

  • While more clinical trials are needed to determine if endogenously created vitamin D could be effective for the prevention and treatment of COVID-19, studies show that vitamin D plays a role in supporting innate and adaptive immune response, decreasing the risk and severity of respiratory infections, and maintaining balance in the Renin-Angiotensin system which helps control inflammatory response in the body.
  • According to Bob Wise, CEO, “We are currently pursuing an ambitious research strategy, working with leading phototherapy and vitamin D experts, to study the impact vitamin D and SOLIUS may have on treating and preventing COVID-19.
  • Vitamin D functions as both a genetic and immune modulator and its widespread impact on different systems in the body are well known, offering a multi-pronged approach for maintaining a healthy immune system.

May 20, 2020

SOLIUS white paper on the potential impact vitamin D may have on treating and preventing COVID-19 has been released  Request white paper here.

SOLIUS notes Vitamin D is not just a nutrient; it’s a hormone with receptors in nearly every cell and tissue of the body. Vitamin D functions as both a genetic and immune modulator and its widespread impact on different systems in the body are well known, offering a multi-pronged approach for maintaining a healthy immune system. Taking oral vitamin D supplements does not show similar results with any consistency. This is likely due to the very different way the body uses sunlight to produce hormones.

Early research suggests a potential link between vitamin D and COVID-19 outcomes. Several correlational studies have found an association between low levels of vitamin D and susceptibility to acute respiratory tract infections. Researchers from Northwestern University found a correlation between vitamin D levels and cytokine storms, a condition caused by an overactive immune system often seen in the most severe COVID-19 patients. Another study from Anglia Ruskin University in the United Kingdom found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries.

While more clinical trials are needed to determine if endogenously created vitamin D could be effective for the prevention and treatment of COVID-19, studies show that vitamin D plays a role in supporting innate and adaptive immune response, decreasing the risk and severity of respiratory infections, and maintaining balance in the Renin-Angiotensin system which helps control inflammatory response in the body.

The SOLIUS technology stimulates the production of vitamin D in the skin using a narrow spectrum of ultraviolet B (UVB) light. This technology can produce 10x more vitamin D than the sun, using 100x less ultraviolet energy. According to Bob Wise, CEO, “We are currently pursuing an ambitious research strategy, working with leading phototherapy and vitamin D experts, to study the impact vitamin D and SOLIUS may have on treating and preventing COVID-19.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy